91.1 F
San Fernando
Thursday, Mar 28, 2024

Amgen Acquires Alantos

Thousand Oaks-based biotechnology firm Amgen announced the completion of its acquisition of Alantos, a private company that develops drugs for diabetes and inflammatory illnesses, is complete. The transaction provides Amgen with Alantos’ DPP-IV inhibitor, which is in clinical development for the treatment of type II diabetes. Because of the acquisition, first announced June 6, Amgen now has Alantos’ matrix metalloproteinases platform for osteoarthritis as well.

Featured Articles

Related Articles